MBX Capital

MBX Capital Research Investment Thesis MBX Capital is an early-stage venture capital fund founded to address the most critical gap in healthcare innovation: the root causes of chronic disease. The fund operates with a explicit thesis that deep health emerges at the convergence of advances in biology, chemistry, AI/ML, robotics, and clinical medicine. Rather than pursuing incremental improvements to existing healthcare infrastructure—automating administrative workflows or virtualizing legacy care models—MBX Capital backs visionary founders building transformative solutions that bend the curve of chronic disease. The fund's analysis is stark: chronic disease now affects over half of all adults in the United States, driven by the collision of human biology, environmental toxins, and a broken healthcare system. Much of today's health innovation remains shallow, pursued through endless automation of administrative workflows or point solutions for individual conditions. MBX Capital rejects this approach, believing the most enduring value—both social and financial—will come from addressing the three fundamental domains where deep health impact is possible. Three Pillars of Deep Health Investment MBX Capital structures its thesis around three critical domains: 1. Biology Within Us - Biotech platforms that move beyond symptom management to decode and reprogram disease itself. This includes novel medicines, precision diagnostics, and research tools that create a more powerful armamentarium for treating complex disease. Portfolio companies like Earli (synthetic biomarkers for cancer detection), Vaxxinity (synthetic peptide vaccines), and Persist AI (AI+robotics for drug formulation screening) exemplify this pillar. 2. Environment Around Us - Technologies that confront the environmental and industrial drivers of disease. These include innovations in chemical safety, water and air quality, sustainable food systems, and replacement of toxic products with safer alternatives. Tidal Vision (green chemistry for pollution abatement) and Vivodyne (organoid-on-chip safety testing) demonstrate this focus. 3. Systems That Care for Us - System-level innovation that delivers durable clinical impact by expanding capacity where it is scarce, bringing advanced therapies to underserved patients, and ending interventions that do more harm than good. Companies like Junction Health (infusion therapy infrastructure for community health centers), Mae Health (maternal health for minorities), and Macro Trials (high-value clinical trial accessibility) exemplify this approach. Stage Focus and Check Size MBX Capital typically invests in companies' first or second institutional rounds, usually before $50M valuation, though they opportunistically participate in later stage financings. Their typical check size ranges from $1M to $4M, depending on company stage and funding need, with a general target of at least 5% ownership in companies they invest. This ownership target reflects their commitment to meaningful partnership rather than passive participation. Stage preferences strongly favor Pre-Seed and Seed rounds, with selective Series A participation, particularly in follow-on situations. Lead Tendency and Investment Approach MBX Capital frequently leads or co-leads early rounds, establishing strong ownership stakes and board relationships. They can also participate as a follow-on investor in larger financings. Based on their portfolio composition (35+ companies) and recent activity (consistent monthly partnership announcements), they demonstrate a clear pattern of round leadership at the seed stage. The fund's track record shows successful exits including Vaxxinity (IPO 2021) and portfolio company acquisitions, indicating ability to support companies through inflection points. Recent Activity and Fund Status MBX Capital crossed $100M in cumulative capital commitments in December 2025, a milestone reached just 4 years after inception. This represents approximately $25M annual deployment capacity, suggesting an actively funded fund. Recent partnership announcements from late 2024 through 2025 include Persist AI, Enoda Cellworks, Juniper, Keebler Health, Tidal Vision, Junction Health, and Examol—demonstrating consistent deployment velocity. Fund status: Actively deploying with significant institutional LP backing evident from the scale reached in such a short timeframe. Portfolio Composition and Co-Investors MBX Capital's 35+ portfolio companies reveal selective co-investor relationships with respected early-stage funds including Village Global, Khosla Ventures, a16z, Sequoia Capital, Tribe Capital, and Initiate Ventures. This co-investor composition reflects the fund's strong reputation in deep health spaces and validates their thesis strength. Portfolio spans approximately equal weight across biotech platforms (Earli, Catena Bio, Vaxxinity, Persist AI, Enoda), AI/diagnostics (Keebler Health, Fathom Health, Eva Tech), healthcare delivery/infrastructure (Junction Health, Arine, Forum, Mae Health), and environmental health (Tidal Vision, Examol, Vivodyne). Geographic Focus MBX Capital invests primarily in the United States with operations headquartered in New York. However, they explicitly state they can invest anywhere in the world for the right opportunity. Notable international investments include Dezy/Smiles.ai (India) and Eva Tech (with LATAM focus), demonstrating willingness to back exceptional founders globally. Team and Organization Investment Team: Gurdane Bhutani , Managing Partner (New York, NY) Zeshan Muhammedi , Managing Partner (Washington, D.C.) The fund operates with a proprietary "Atom Network" of hundreds of scientific and clinical experts—comprising research scientists, clinicians, industry veterans, and specialized domain experts—who help source opportunities, conduct technical due diligence, and provide ongoing operational support to portfolio companies. This differentiated resource represents a meaningful competitive advantage in early-stage deep health investing. Decision Process and Timeline While specific formal decision timelines are not explicitly stated, the fund's demonstrated ability to deploy $25M+ annually suggests a reasonably efficient decision-making process. The pattern of monthly partnership announcements and the breadth of thesis (sector-agnostic by design) suggest efficient decision-making without excessive lag. Founder Preferences and Anti-Thesis MBX Capital explicitly targets "visionary deep health founders" with clear vision to address root causes of disease. They prefer founders with scientific or clinical expertise, though not exclusively required if the vision is sufficiently compelling. They explicitly avoid companies pursuing incremental healthcare automation, pure administrative software without deep health impact, and symptom management approaches without root cause focus.